What insulin sensitivity is
Insulin sensitivity is how effectively your cells respond to insulin's signal to take up glucose, suppress liver glucose production, and store fat. High sensitivity = small amounts of insulin produce large effects. Low sensitivity (insulin resistance) = body must produce more insulin to achieve the same effect, leading to chronically elevated insulin (hyperinsulinemia), which has its own pathological consequences.
Why it matters
Insulin resistance is the metabolic root of:
- Type 2 diabetes
- Cardiovascular disease (independent of glycemia)
- Fatty liver disease (NAFLD/MASH)
- PCOS
- Metabolic syndrome
- Many cancers
- Cognitive decline
Treating insulin resistance prevents or reverses many downstream conditions. GLP-1 therapy is one of the most effective interventions available.
Direct effects of GLP-1
Mechanisms not requiring weight loss:
- Glucose-dependent insulin release, beta cells release insulin only when glucose is high, smoothing post-meal spikes without causing low blood sugar
- Glucagon suppression, alpha cells reduce glucagon output, so the liver doesn't dump glucose at the wrong moment
- Slowed gastric emptying, food enters bloodstream more gradually, reducing peak glucose
- Direct GLP-1R effects on insulin signaling pathways in some tissues
Indirect effects via weight loss and inflammation
- Visceral fat reduction, visceral adipose releases inflammatory cytokines that interfere with insulin signaling. Reducing it improves sensitivity.
- Reduced inflammatory cytokines, IL-6, TNF-α reductions improve insulin signaling at the receptor and downstream
- Reduced ectopic fat, fat in liver and muscle disrupts insulin signaling locally. Reducing it improves systemic sensitivity.
- Improved mitochondrial function, partly downstream of metabolic improvement
Trial data
- Fasting insulin drops 30-50% in major trials
- HOMA-IR (homeostatic model assessment of insulin resistance) drops 40-60%
- HbA1c drops 1.5-2.5 percentage points
- Postprandial glucose excursions flatten dramatically
- Effect appears within weeks, before substantial weight loss
What to measure
To track insulin sensitivity:
- Fasting insulin, direct measure (optimal <7 mIU/mL)
- Fasting glucose, combined with insulin to calculate HOMA-IR
- HbA1c, 3-month average glucose
- Triglyceride/HDL ratio, proxy for insulin resistance (optimal <2)
- OGTT (oral glucose tolerance test), direct functional test
OPTML metabolic panels include fasting insulin and HbA1c routinely.
The clinical pearl: Fasting insulin is the most underused test in metabolic medicine. It often shows insulin resistance years before HbA1c rises into the prediabetes range. Patients who think they're "fine" because their HbA1c is normal often have substantially elevated fasting insulin, the early warning that GLP-1 therapy can correct.
Bottom line
GLP-1 therapy improves insulin sensitivity through multiple mechanisms, direct effects on insulin and glucagon release, plus indirect effects from weight loss and inflammation reduction. The improvements in fasting insulin, HOMA-IR, and HbA1c are substantial and rapid. Insulin sensitivity improvement is one of the cleanest mechanistic stories of GLP-1 therapy and the foundation of its broader cardiovascular and longevity benefits.